• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Minerva Surgical Inc.

    12/26/23 12:05:19 PM ET
    $UTRS
    Computer Software: Prepackaged Software
    Technology
    Get the next $UTRS alert in real time by email
    S-8 POS 1 utrs_s8_pos_deregister_s.htm S-8 POS S-8 POS

     

     

     

     

    Registration No. 333-260471

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Minerva Surgical, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

     

    26-3422906

    (State or other jurisdiction of incorporation)

     

    (I.R.S. Employer Identification No.)

     

     

     

    4255 Burton Dr., Santa Clara, CA

    95054

    (Address of principal executive offices)

    (Zip Code)

     

    Minerva Surgical, Inc. 2008 Stock Plan
    Minerva Surgical, Inc. 2021 Equity Incentive Plan
    Minerva Surgical, Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plan)

     

    Todd Usen

    Copies to:

    President and Chief Executive Officer

    Joseph Wolfson

    Minerva Surgical, Inc.

    Sunjeet S. Gill

    4255 Burton Dr.

    Stevens & Lee, P.C.

    Santa Clara, CA 95054

    1500 Market Street, East Tower

    (855) 646-7874

    Philadelphia, PA 19102

    (Name, address and telephone number, including area code, of agent for service)

    (215) 575-0100

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ◻

    Accelerated filer ◻

    Non-accelerated filer ☒

    Smaller reporting company ☒

    Emerging growth company ☒

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    This Registration Statement shall become effective upon filing in accordance with Rule 464 promulgated under the Securities Act of 1933, as amended.

     

    DEREGISTRATION OF SHARES

     

    The class of securities to which this Registration Statement on Form S-8 (File No. 333-260471) (the “Registration Statement”) relates is held by fewer than 300 shareholders of record. Minerva Surgical, Inc. (the “Company”) is filing this Post-Effective Amendment No. 1 to the Registration Statement to deregister all of the shares of common stock, $0.001 par value, of the Company, and related stock options therefor, registered under the Registration Statement that remain unissued under each of the Minerva Surgical, Inc. 2008 Stock Plan, the Minerva Surgical, Inc. 2021 Equity Incentive Plan and the Minerva Surgical, Inc. 2021 Employee Stock Purchase Plan.

     

     

     


     

    SIGNATURES

     

    The Registrant. Pursuant to the requirements of the Securities Exchange Act of 1933, as amended, the Registrant certifies that is has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Santa Clara, State of California, on December 26, 2023.

     

     

     

     

    MINERVA SURGICAL, INC.

     

     

     

     

     

     

    Date: December 26, 2023

    /s/ Todd Usen

     

    Todd Usen

     

    President and Chief Executive Officer

     

    (Duly Authorized Representative)

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

     

     

     

     

    By:

    /s/ Uri Geiger

    By:

    /s/ Todd Usen

     

    Uri Geiger

     

     

    Todd Usen

     

    Chairman of the Board of Directors

     

     

    President and Chief Executive Officer

     

     

     

     

    Director

     

     

     

     

    (Principal Executive Officer)

     

     

     

     

     

    Date: December 26, 2023

     

    Date: December 26, 2023

     

     

     

     

     

    By:

    /s/ Joel Jung

     

    By:

    /s/ Ali Behbahani

     

    Joel Jung

     

     

    Ali Behbahani

     

    Chief Financial Officer

     

     

    Director

     

    (Principal Financial and Accounting Officer)

     

     

     

     

     

     

     

     

    Date: December 26, 2023

     

    Date: December 26, 2023

     

     

     

     

     

    By:

    /s/ Daniel Cohen

     

    By:

    /s/ Catherine Coste

     

    Daniel Cohen

     

     

    Catherine Coste

     

    Director

     

     

    Director

     

     

     

     

     

    Date: December 26, 2023

     

    Date: December 26, 2023

     

     

     

     

     

    By:

    /s/ Niquette Hunt

     

    By:

    /s/ Derrick Sung

     

    Niquette Hunt

     

     

    Derrick Sung

     

    Director

     

     

    Director

     

     

     

     

     

    Date: December 26, 2023

     

    Date: December 26, 2023

     

     

     


    Get the next $UTRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UTRS

    DatePrice TargetRatingAnalyst
    3/9/2022$17.00 → $12.00Overweight
    Piper Sandler
    12/3/2021$17.00 → $12.00Outperform
    SVB Leerink
    11/16/2021$17.00Outperform
    SVB Leerink
    11/16/2021$15.00Buy
    UBS
    11/16/2021$14.00Overweight
    JP Morgan
    11/16/2021$17.00Overweight
    Piper Sandler
    More analyst ratings

    $UTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler reiterated coverage on Minerva Surgical with a new price target

      Piper Sandler reiterated coverage of Minerva Surgical with a rating of Overweight and set a new price target of $12.00 from $17.00 previously

      3/9/22 6:38:44 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SVB Leerink reiterated coverage on Minerva Surgical with a new price target

      SVB Leerink reiterated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $12.00 from $17.00 previously

      12/3/21 9:34:35 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SVB Leerink initiated coverage on Minerva Surgical with a new price target

      SVB Leerink initiated coverage of Minerva Surgical with a rating of Outperform and set a new price target of $17.00

      11/16/21 7:59:25 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer

      SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, announced today the appointment of Kaile Zagger as its new Chief Commercial Officer. Ms. Zagger's leadership will help guide the strategic growth of the company and advance its position as a leader in women's healthcare solutions. "We are excited to have Kaile as our new Chief Commercial Officer for her proven track record of driving exponential growth and productivity, while delivering bottom line results," said Todd Usen, president and CEO of Minerva Surgical. "Beyond her pro

      3/21/23 4:05:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Announces Retirement of CEO David Clapper and Appointment of Todd Usen as Company President and CEO

      SANTA CLARA, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that David Clapper, who has served as President and Chief Executive Officer since 2011, has chosen to retire. The Company's board of directors (the Board) has appointed industry executive Todd Usen as President and Chief Executive Officer of Minerva Surgical and a member of the Board to succeed Mr. Clapper effective January 2, 2023. To ensure a smooth leadership transition, Mr. Clapper will continue to serve in his role through Mr. Usen's first day of employment an

      12/28/22 6:00:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Announces Appointment of Derrick Sung, Ph.D. to Board of Directors

      SANTA CLARA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) ("Minerva Surgical" or the "Company"), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today announced that the board of directors (the "Board") of Minerva Surgical has appointed Derrick Sung, Ph.D. to serve as a Class II director, with a term expiring at the 2023 annual meeting of stockholders or until his successor has been duly elected and qualified. The Board has affirmatively determined that Dr. Sung is an independent director pursuant to the listing standards of The NASDAQ Stock Market. "We are excited to have Derrick Sung, Ph.D. join the Board of Directo

      7/21/22 8:00:00 AM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    Financials

    Live finance-specific insights

    See more
    • Minerva Surgical Reports Second Quarter 2023 Financial Results

      SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o

      8/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports First Quarter 2023 Financial Results

      SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co

      5/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical to Announce First Quarter 2023 Financial Results

      SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique pe

      4/18/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

      SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

      9/28/23 4:43:42 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

      SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

      7/6/23 8:21:56 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13D/A filed by Minerva Surgical Inc. (Amendment)

      SC 13D/A - MINERVA SURGICAL INC (0001452965) (Subject)

      7/6/23 5:19:24 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Minerva Surgical Inc.

      15-12G - MINERVA SURGICAL INC (0001452965) (Filer)

      1/4/24 4:32:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 25 filed by Minerva Surgical Inc.

      25 - MINERVA SURGICAL INC (0001452965) (Filer)

      12/26/23 4:30:25 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form S-8 POS filed by Minerva Surgical Inc.

      S-8 POS - MINERVA SURGICAL INC (0001452965) (Filer)

      12/26/23 12:05:19 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Minerva Surgical Reports Third Quarter 2023 Financial Results

      SANTA CLARA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023. Third Quarter Highlights: Reported revenue of $12.0 million in the third quarter of 2023, compared with revenue of $12.6 million in the third quarter of 2022Increased Symphion product revenue by 19% compared to the third quarter of 2022 "As we head into the fourth quarter of 2023, I am very pleased with the progress we have made to date in expanding the reach of our Sym

      11/13/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports Second Quarter 2023 Financial Results

      SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion and Minerva ES product revenue by 7% compared to the second quarter of 2022Realigned the commercial organization to better serve customer needs and drive sustainable growth "From o

      8/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • Minerva Surgical Reports First Quarter 2023 Financial Results

      SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (NASDAQ:UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported first quarter financial results for the period ended March 31, 2023. First Quarter and Recent Business Highlights: Reported revenue of $12.5 million in the first quarter of 2023, compared with revenue of $10.9 million in the first quarter of 2022Increased revenue for all product lines compared to the first quarter of 2022, with Symphion increasing 20% and Minerva ES increasing 18%Appointed Todd Usen as Chief Executive Officer at the start of 2023 co

      5/2/23 4:01:00 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology

    $UTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Cohen Daniel claimed ownership of 122,189,638 shares

      3 - MINERVA SURGICAL INC (0001452965) (Issuer)

      3/14/23 5:37:19 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4: New Enterprise Associates 13 Lp bought $5,000,000 worth of shares (24,437,927 units at $0.20)

      4 - MINERVA SURGICAL INC (0001452965) (Issuer)

      2/10/23 9:25:19 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 3: New insider Accelmed Partners Ii L.P. claimed ownership of 122,189,638 shares

      3 - MINERVA SURGICAL INC (0001452965) (Issuer)

      2/9/23 4:28:55 PM ET
      $UTRS
      Computer Software: Prepackaged Software
      Technology